Abstract:The revolutionary nanotechnology brings hope to posterior segment ocular diseases. This review delves into the challenges of conventional drug delivery and the advantages of diverse nanomaterials in enhancing drug stability, targeting, and permeability by targeting VEGF, ROS, macrophages. Focusing on the latest developments, this paper examines nanomedicine's potential to transform therapeutic approaches and improve global visual health. Funduscopic diseases, including diabetic retinopathy (DR) and age‐related macular degeneration (AMD), significantly impact global visual health, leading to impaired vision and irreversible blindness. Delivering drugs to the posterior segment of the eye remains a challenge due to the presence of multiple physiological and anatomical barriers. Conventional drug delivery methods often prove ineffective and may cause side effects. Nanomaterials, characterized by their small size, large surface area, tunable properties, and biocompatibility, enhance the permeability, stability, and targeting of drugs. Ocular nanomaterials encompass a wide range, including lipid nanomaterials, polymer nanomaterials, metal nanomaterials, carbon nanomaterials, quantum dot nanomaterials, and so on. These innovative materials, often combined with hydrogels and exosomes, are engineered to address multiple mechanisms, including macrophage polarization, reactive oxygen species (ROS) scavenging, and anti‐vascular endothelial growth factor (VEGF). Compared to conventional modalities, nanomedicines achieve regulated and sustained delivery, reduced administration frequency, prolonged drug action, and minimized side effects. This study delves into the obstacles encountered in drug delivery to the posterior segment and highlights the progress facilitated by nanomedicine. Prospectively, these findings pave the way for next‐generation ocular drug delivery systems and deeper clinical research, aiming to refine treatments, alleviate the burden on patients, and ultimately improve visual health globally.

Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review

Nanotechnology-Ocular Devices for Glaucoma Treatment: A Literature Review

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies

Nanomedicines for the Treatment of Glaucoma: Current Status and Future Perspectives

Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems

Review: Neuroprotective Nanocarriers in Glaucoma

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Nanomedicine in glaucoma treatment; Current challenges and future perspectives

Newer advances in medical management of glaucoma

Nanotechnology-based Strategies for Treatment of Ocular Disease

Point-of-Care Nanoplatforms for Glaucoma and Age-Related Macular Degeneration: Clinical Implications and Emerging Concepts

Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease

Research Progress of Nano Delivery Systems for Intraocular Pressure Lowering Drugs

Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress

Therapeutic strategies for glaucoma and optic neuropathies

Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma, review and update

Gene therapy for glaucoma: Targeting key mechanisms

Current opinion in ophthalmology: novel glaucoma devices in the pipeline

A review on nanotechnology based ophthalmic drug delivery system